Patent Issued to FibroBiologics for Osteoporosis Treatment

FibroBiologics Inc. has secured a new U.S. patent for treating osteoporosis using fibroblast cell therapy.

U.S. Patent No. 12,544,407 B2, “Fibroblast Cell Therapy for Treatment of Osteoporosis,” covers methods of treating bone diseases or disorders—including osteoporosis—by administering fibroblast cells. The claims encompass systemic or local administration of fibroblasts, including modified fibroblasts, to modulate bone remodeling by inhibiting osteoclast activity and/or promoting osteoblast activity.

Specifically, the issued patent includes claims directed to:

• Methods of treating osteoporosis by administering fibroblasts expressing recombinant CXCR4 or recombinant hTERT.
• Dedifferentiated fibroblasts generated through expression of OCT4, NANOG, and/or SOX2.
• Fibroblasts selected for specific marker profiles, including CD73, CD56, CD140, CD105, CD90, CD36, and CD146.
• Administration of fibroblasts systemically or locally.
• Combination therapy with anti-inflammatory agents, including NF-kappa B inhibitors

Osteoporosis is a chronic, progressive condition characterized by reduced bone mass and bone structure deterioration, leading to increased fracture risk. The newly issued patent supports FibroBiologics’ approach to leveraging fibroblasts as therapeutic agents that modulate bone resorption and bone formation pathways, including inhibition of RANK ligand (RANKL)-mediated osteoclast activation.

“This patent is more than a milestone, it’s a bold step forward in our mission to rethink what’s possible in regenerative medicine,” FibroBiologics Founder/CEO Pete O’Heeron stated. “Osteoporosis impacts millions of lives across the globe, often quietly and profoundly. We see fibroblasts not just as cells, but as catalysts for change, with the potential to transform the way we treat bone degeneration by tackling both inflammation and the rebuilding process at its core. That’s the kind of innovation that truly excites us.”

With this issuance, FibroBiologics further reinforces its strategy of developing proprietary fibroblast cell therapies designed to address significant unmet medical needs.

Based in Houston, FibroBiologics is a clinical-stage biotechnology company developing treatments and seeking potential cures for chronic diseases using fibroblast cells and fibroblast-derived materials. FibroBiologics holds more than 270 U.S. and internationally issued patents/patents pending across various clinical pathways, including wound healing, multiple sclerosis, disc degeneration, psoriasis, orthopedics, human longevity, and cancer.